Society guideline links: Pneumococcal vaccination in adults

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

International

●World Health Organization (WHO): Position paper on pneumococcal conjugate vaccines (2019)

Canada

●National Advisory Committee on Immunization (NACI): An Advisory Committee Statement (ACS) – Update on the use of pneumococcal vaccines in adults 65 years of age and older: A public health perspective (2018)

●NACI: An Advisory Committee Statement (ACS) – Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older: Interim recommendation (2016)

●Public Health Agency of Canada (PHAC): Canadian Immunization Guide – Pneumococcal vaccine (2016)

●NACI: An Advisory Committee Statement (ACS) on re-immunization with polysaccharide 23-valent pneumococcal vaccine (Pneu-P-23) (2015)

●NACI: An Advisory Committee Statement (ACS) on the use of pneumococcal vaccines – Addition of asthma as a high-risk condition, update (2014)

●NACI: An Advisory Committee Statement (ACS) on the conjugate pneumococcal vaccine – 13 valent in adults (2013)

United States

●Advisory Committee on Immunization Practices (ACIP): Pneumococcal vaccine recommendations

●Centers for Disease Control and Prevention (CDC): Epidemiology and Prevention of Vaccine-Preventable Diseases ("The Pink Book") – Pneumococcal disease (2021)